Optimizing therapy in previously treated non-small cell lung cancer Journal Article
| Author: | Miller, V. A. |
| Article Title: | Optimizing therapy in previously treated non-small cell lung cancer |
| Abstract: | The past decade has seen the identification of several novel cytotoxic agents. More recently, targeted therapies with single-agent activity or that enhance the efficacy of chemotherapy in advanced non-small cell lung cancer have been identified. These agents have been, or are undergoing, active testing alone and in combination in both loco-regional and advanced disease as initial therapy and after failure of cytotoxic therapy. The cytotoxic agents docetaxel, pemetrexed, and topotecan, as well as the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, have been evaluated in phase III trials in previously treated populations. This review summarizes the results of these phase III studies with a particular focus on predictors of favorable outcome, attempts to provide a rational approach to therapeutic selection in this patient population, and discusses ongoing pivotal trials and future strategies in this field. © 2006 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; gene mutation; clinical trial; disease course; neutropenia; review; salvage therapy; cytotoxic agent; erlotinib; drug efficacy; drug safety; drug targeting; paclitaxel; cancer adjuvant therapy; topotecan; cancer staging; adenocarcinoma; neoplasm recurrence, local; gene amplification; anemia; bone marrow suppression; blood toxicity; gastrointestinal symptom; lung non small cell cancer; neuropathy; antineoplastic combined chemotherapy protocols; carcinoma, non-small-cell lung; lung neoplasms; epidermal growth factor receptor; lung cancer; dexamethasone; receptor, epidermal growth factor; food and drug administration; ifosfamide; docetaxel; protein kinase inhibitors; disease severity; lung adenocarcinoma; gefitinib; sepsis; platinum derivative; folic acid; navelbine; k ras protein; alopecia; pemetrexed; disease exacerbation; epidermal growth factor receptor kinase inhibitor; cyanocobalamin |
| Journal Title: | Seminars in Oncology |
| Volume: | 33 |
| Issue: | Suppl.1 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2006-02-01 |
| Start Page: | S25 |
| End Page: | S31 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2005.12.005 |
| PUBMED: | 16472706 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 4 June 2012" - "CODEN: SOLGA" - "Source: Scopus" |
